Search research articles
Contact Us
Filters
Showing results (151-160 of 192) with videos related to
Page
of 20
Sort By:
Clinical Lung Cancer
|
March 2, 2020
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 12, 2026
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria
Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada, et al.
Cancer Science
|
January 30, 2026
Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, et al.
Clinical Lung Cancer
|
August 13, 2024
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
Hayato Kawachi, Motohiro Tamiya, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2025
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis
Toshiya Fujisaki, Eisaku Miyauchi, Gen Kida, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
Yuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
BMC Cancer
|
April 2, 2021
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Clinical Lung Cancer
|
June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Anticancer Research
|
December 8, 2020
Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy
Masahiro Morimoto, Kazumi Nishino, Kentaro Wada, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 192) with videos related to
Sort By:
Page
of 20
Clinical Lung Cancer
|
March 2, 2020
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 12, 2026
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria
Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada, et al.
Cancer Science
|
January 30, 2026
Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, et al.
Clinical Lung Cancer
|
August 13, 2024
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
Hayato Kawachi, Motohiro Tamiya, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2025
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis
Toshiya Fujisaki, Eisaku Miyauchi, Gen Kida, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
Yuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
BMC Cancer
|
April 2, 2021
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Clinical Lung Cancer
|
June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Anticancer Research
|
December 8, 2020
Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Αfter Definitive Chemoradiotherapy
Masahiro Morimoto, Kazumi Nishino, Kentaro Wada, et al.
Page
of 20